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ABSTRACT 
 
Cellular metabolism results in the production of reactive oxygen species (ROS) as 
byproducts and can damage proteins, lipids, and DNA. Cells utilize a number of enzymes and 
small molecules to scavenge ROS and prevent and repair damage that has occurred. To better 
understand the role three of these proteins play in responding to ROS, we examined the activity 
of Cu/Zn superoxide dismutase, apurinic endonuclease, and estrogen receptor α in the central 
nervous system. Our studies demonstrate that oxidative protein damage in the spinal cord 
occurred prior to the appearance of motor symptoms in mice that express a mutant form of 
Cu/Zn superoxide dismutase and subsequently develop symptoms of amyotrophic lateral 
sclerosis. Additionally, we show increased apurinic endonuclease expression in the cerebral 
cortex of mice that had been ovariectomized, treated with 17β-estradiol, and then exposed to 
hypoxia. A decline in oxidative DNA damage occurred which we believe was the result of the 
17β-estradiol-mediated increase in apurinic endonuclease expression. Finally, our work shows 
that estrogen receptor α protein expression in the cerebral cortex was stable in aging, hormonally 
intact females and this estrogen receptor α protein was functional. Altogether, these studies 
demonstrate the importance of understanding the impact of ROS-induced damage on human 
health and disease and provide insight to develop methods of prevention and treatment for 
neurodegenerative disorders.  	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CHAPTER ONE: 
Introduction 
 
Molecular oxygen is a necessary component for the many oxidation-reduction reactions 
that sustain life. All aerobic cells utilize oxygen as an electron acceptor during oxidative 
phosphorylation. Specific free radical molecules known as reactive oxygen species (ROS) 
contain oxygen and are constantly produced in cells throughout the body.  Examples of ROS 
include superoxide, which is the most abundant ROS, hydrogen peroxide, hydroxyl radical, nitric 
oxide, and peroxynitrite [1]. ROS have several important biological roles in the healthy cell 
including cellular signaling and host defense.  
Biological roles of ROS 
There is a misconception that ROS are only toxic byproducts of aerobic respiration but 
increasing evidence demonstrates that they are necessary for several physiological activities such 
as cellular signaling and phagocytosis. For example, hydrogen peroxide serves as a second 
messenger for MAP kinase activation and tyrosine phosphorylation [2-5]. Hydrogen peroxide is 
a highly diffusible molecule that can be quickly synthesized or broken down in response to 
stimuli, good qualities of a second messenger [2]. 
ROS participate in cytokine/growth factor action and secretion, ion transport, 
transcription, and apoptosis [6]. The targets of ROS involved in cellular signaling often include 
proteins such as thiols in G-proteins [7], transcription factors [8], and ion channels [9]. The 
specificity of targeted ROS signaling is based on several factors including the reduction potential 
of the target, the availability of other reactive species, a consensus sequence of redox active 
cysteine residues [10], or the placement of a particular cysteine residue [7]. ROS levels are 
regulated by the activity of their endogenous scavengers. These scavengers must not only inhibit 
ROS but must also modify and transport ROS involved in cellular communication [6]. Optimal 
NF-κB activation requires the controlled activity of glutathione [10]. Superoxide dismutase 
converts superoxide to hydrogen peroxide which can then form hydroxyl radical via the Fenton 
reaction. Thus regulation of ROS-activity occurs at three levels: 1) generation of species, 2) 
targeting, and 3) scavenger activity [6]. 
 Another physiological role of ROS is in phagocytosis and immune function. Superoxide, 
hydrogen peroxide, and nitric oxide participate in host defense in neutrophils, eosinophils and 
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other polymorphonuclear phagocytes. Following activation via phosphorylation, NADPH 
oxidase produces superoxide in phagocytic cells. NADPH oxidase 2 produces hydrogen peroxide 
which then acts as a chemotactic factor for polymorphonuclear leukocytes [11]. Once at the 
appropriate region, ROS can also help to keep leukocytes and phagocytes in the area by 
inhibiting cell motility [12].  
Oxidative stress 
 While ROS have biologically useful activities, the accumulation or abundance of ROS 
can lead to oxidative stress, a deleterious state in which the reduced intracellular environment is 
compromised. As superoxide is continually being generated during ATP production in 
mitochondria, the accumulation of ROS becomes a concern [13]. The mitochondrial respiratory 
chain, or electron transport chain, is composed of five protein complexes located within the inner 
membrane and arranged in order of increasing reduction potential [14]. During respiration 
electrons are passed from one complex to the next, but some electrons escape and participate in 
side reactions with molecular oxygen, partially reducing it to yield superoxide. Complexes I and 
III of the respiratory chain are the major sites of superoxide production from oxidative 
phosphorylation [15,16]. 
 In addition to the large production of superoxide from the electron transport chain 
reactions of the inner mitochondrial membrane, hydrogen peroxide is produced in large 
quantities by monoamine oxidase in the outer membrane [13,14]. This enzyme catalyzes the 
oxidative deamination of biogenic amines which include the catecholamines, serotonin, and 
histamine. In dopaminergic neurons this enzyme is particularly active due to dopamine turnover 
[14]. Dopamine catabolism produces hydrogen peroxide as a byproduct and thus contributes to 
the development of Parkinson’s disease. Thus, ROS are continually being generated both in the 
mitochondrial matrix and the cytosol. 
ROS-induced damage 
Cellular macromolecules including proteins, DNA, and lipids can become damaged 
during conditions of oxidative stress. While oxidation may serve regulatory functions in some 
cases, such as for the transcription factors NF-κB and AP-1 and in protein degradation, in other 
instances oxidation causes irreversible damage [17-19]. 
The amino acid residues histidine, lysine, arginine, proline, threonine, cysteine, aspartate, 
and tyrosine can all be modified by ROS. Examples of oxidative protein alterations include 
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carbonylation, thiol oxidation, and formation of isoaspartate and nitrotyrosine. Unlike the 
reversible oxidation of cysteine thiols, carbonylation of amino acid side chains in proteins is an 
example of irreversible ROS-induced protein damage. The proteasome [20] or autophagosomes 
[21] are utilized to degrade irreversibly oxidized macromolecules. Several oxidizing agents are 
involved in the formation of this damage including peroxynitrite, nitric oxide, and nitrite [22-25]. 
Oxidative DNA damage can occur as single base lesions, aldehyde adducts, strand breaks, 
or as the loss of a base, an apurinic site. These structural alterations are primarily mediated by 
hydroxyl radical, singlet oxygen, and hypochlorous acid as the main types of ROS that have been 
shown to interact with and cause damage to DNA [26,27]. ROS-induced DNA damage can 
include base pair mutations, mispairing, deletions, or insertions. Both nuclear and mitochondrial 
DNA are subject to ROS-induced damage, but the proximity of mitochondrial DNA and lack of 
repair proteins make it especially vulnerable to ROS-induced damage [13]. Single base, ROS-
induced DNA damage is repaired via the short patch arm of the base excision repair pathway. 
Damage to three or more nucleotides is repaired via the long patch base excision repair pathway 
[28].  
 Lipids are also susceptible to ROS-induced damage. For example, peroxidation of 
polyunsaturated fatty acids such as arachidonatic acid can be induced by hydroxyl radical, 
peroxynitrite, and other potent oxidants [29]. When these oxidants react with lipids, hydrogen 
atoms are removed and the addition of oxygen to the lipid radical results in production of 
isoprostanes, stable prostaglandin-like products formed as a result of oxidative damage to 
polyunsaturated fatty acids [29,30]. The breakdown of lipid peroxidation produces 
malondialdehyde or other reactive aldehydes [31].  
Biological implications of oxidative stress and ROS-induced damage 
 The biological implications of ROS dysregulation and damage include the development 
of cancer, inflammation, cardiovascular disease, neurodegenerative diseases, and many other 
conditions sensitive to the redox state of the cell. Oxidative stress is known to play an important 
role in the development and progression of cancer. In fact, cancer cells have increased levels of 
ROS, further enhancing the proliferation and genetic instability of tumor cells [32]. Oxidative 
stress has been implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer’s 
disease, Parkinson’s disease, amyotrophic lateral sclerosis, and stroke [33]. Similar types of 
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damage to proteins, DNA, and lipids are present in each of these disorders, indicating a similar 
origin and cascade of events that occur in each [34,35]. 
Oxidative stress response proteins 
 Cells have developed a system of enzymatic and non-enzymatic methods to restrict ROS 
production and utilization to appropriate subcellular locations, times, levels, molecular species, 
and for appropriate durations [12]. Many of the proteins involved in reducing ROS production, 
catabolizing ROS, repairing ROS-induced damage, or degrading macromolecules that cannot be 
repaired are known as antioxidants. These include superoxide dismutases, catalases, and 
enzymes of the glutathione and thioredoxin redox cycles. In addition to these antioxidant 
enzymes, small molecules including ascorbate, pyruvate, and α-ketoglutarate react with ROS 
non-enzymatically and can be recycled or replenished, giving them a ROS-buffering capacity 
[12]. 
 Our laboratory previously identified five oxidative stress response proteins that associate 
with the DNA-bound estrogen receptor α (ERα) and influence estrogen responsiveness (Fig. 1.1; 
[36,37]). These oxidative stress response proteins include Cu/Zn superoxide dismutase (SOD1), 
thioredoxin (Trx), thioredoxin reductase (TrxR), protein disulfide isomerase (PDI), and apurinic 
endonuclease (Ape1). Each protein is responsible for reducing levels of ROS, maintaining a 
reduced intracellular environment, or repairing ROS-induced damage.  For example, SOD1 is the 
first line of defense against ROS, and reduces superoxide to hydrogen peroxide [38]. Hydrogen 
peroxide is further reduced to water by cellular enzymes including catalase (Cat) and 
peroxiredoxins (Prx) [39]. Thioredoxin (Trx) is the major disulfide reductase and is responsible 
for reducing oxidized Prx to maintain its activity [40]. Thioredoxin reductase (TrxR) reduces Trx 
that has been oxidized by utilizing NADPH as its source of electrons. If oxidative stress occurs 
within the cell, proteins may become oxidized. When this occurs, Trx, TrxR, Ape1, and PDI help 
to reduce proteins to their native conformation [18,41].  
One protein that cells utilize to reduce oxidative stress and repair damage is Ape1. This is a 
multifunctional protein that is necessary for base excision repair of DNA and is involved in the 
regulation of transcription factors via redox mechanisms [42,43]. The DNA repair function of Ape1 is 
especially important in the brain and neurons since these are post-mitotic cells and thus rely heavily on 
the base excision repair (BER) pathway to maintain DNA integrity [44-46]. The BER pathway repairs 
damage to single nucleotides and apurinic sites in DNA. BER is initiated by a DNA glycosylase when it 
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hydrolyzes the N-glycosylic bond between the sugar molecule and DNA base leaving an apurinic site 
that is recognized by Ape1 [47]. Next, Ape1 hydrolyzes the phosphodiester bond in the DNA backbone 
5` to the apurinic site and DNA polymerase β then inserts an intact nucleotide [48-52]. DNA ligase seals 
the backbone and thus completes BER [53]. The brain is an especially vulnerable organ for ROS-
induced damage because it is the most metabolically active organ in the body. This high metabolic 
activity results in greater ROS production and oxidative stress.  
Ape1 is also important in reducing oxidized proteins and maintaining transcription 
factors in a reduced, active state. Studies have demonstrated that Ape1 facilitates DNA binding 
of p53, NFκB, Fos, Jun, and HIF1α [54-57]. When cysteine residues become oxidized, 
transcription factors are no longer able to recognize or bind to their respective DNA sequences. 
Once this occurs, Ape1 can directly reduce oxidized transcription factors and also assists other 
reducing proteins such as Trx and glutathione by binding to select transcription factors, 
enhancing reduction of their cysteine residues, and increasing their DNA binding activity [19]. 
Thus, Ape1 is involved in transcriptional regulation as well as DNA repair and maintenance of 
protein structure and function. 
 Another oxidative stress response protein I have examined in my studies is SOD1. While 
three forms of superoxide dismutase exist two are cellular, SOD1 and SOD2, and a third is 
extracellular, SOD3 [38]. SOD1 is mainly considered a cytoplasmic protein and utilizes copper 
and zinc at its catalytic center to reduce superoxide to hydrogen peroxide. SOD1 responds to a 
variety of chemical and biologic stressors including UVB and irradiation [58-60], hydrogen 
peroxide [61], ozone [62], and nitric oxide [63]. The importance of SOD1 to respond to oxidative 
stimuli is highlighted in studies in which motor neurons from SOD1 deficient mice exhibit 
increased susceptibility to oxidative stress [64]. Furthermore, multiple mutations in the SOD1 
gene are known to contribute to the development of amyotrophic lateral sclerosis (ALS; [65,66]). 
Amyotrophic Lateral Sclerosis 
While it is known that oxidative stress plays a role in stroke, Parkinson’s disease, 
Alzheimer’s disease, and ALS, alterations in SOD1 expression and activity have also been linked 
to neurodegenerative diseases such as familial ALS and Alzheimer’s disease [46,67,68]. Familial 
ALS is linked to mutations in SOD1, many of which are missense mutations and some that 
render the enzyme nearly inactive [65,66]. It has been suggested that upper motor neurons in the 
cerebral cortex and lower motor neurons in the brainstem and spinal cord are damaged by 
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oxidative stress resulting in degeneration of these neurons [69,70]. Symptoms of ALS include 
muscle weakness, difficulty walking, slurred speech, and loss of dexterity. Paralysis and death 
generally occur within three to five years from the onset of these symptoms due to the 
progressive atrophy of affected muscles [71,72].  
Some ALS-associated mutations interfere with the ability of SOD1 to dismutate 
superoxide to hydrogen peroxide and can result in the accumulation of superoxide [73-75]. 
Excess superoxide can then react with nitric oxide to form peroxynitrite (OONO-) which is 
capable of nitrosylating tyrosine residues and altering protein structure and function (Fig. 1.2; 
[33]). Because ROS are short lived and difficult to measure directly, the results of the damage 
they inflict are often used as a measure of the relative amount of oxidative stress present.  
While the aggregation of SOD1 in ALS and its symptoms are well documented, the 
development, progression, and upstream processes that contribute to SOD1 aggregation and ALS 
symptoms are not well understood.  Based on the knowledge that some SOD1 mutations 
associated with ALS prevent the enzyme from dismutating superoxide and that the accumulation 
of superoxide can result in nitrosylation of tyrosine residues, I hypothesized that oxidative 
protein damage might increase in transgenic mice that express a mutant form of SOD1 compared 
with wild type mice.  
SOD1 and neuroprotection 
 Previous studies have demonstrated that SOD1 protects the brain from 
ischemia/reperfusion injury or other neurodegenerative event. Work conducted by Pak Chan and 
coworkers using transgenic mice that overexpress SOD1 shows that infarct size and brain edema 
are decreased in transgenic mice compared to nontransgenic mice [76,77]. Furthermore, the loss 
of SOD1 in mice increases infarct volume, brain swelling and neuronal cell death following 
ischemia [78]. Additional studies have demonstrated that SOD1 is important in repairing injury 
to motor neurons and that this is dependent on SOD1 gene dosage [64]. These studies reveal the 
importance of SOD1 activity in preventing or repairing damage following neuronal injury. 
 Additional studies have provided insight to define how SOD1 mediates its 
neuroprotective effects. Chan and coworkers observed that levels of active glutathione were 
significantly increased following transient ischemia in the penumbra region of transgenic mice 
that over express SOD1 compared to non-transgenic mice [76,77]. These studies demonstrate a 
role for superoxide radicals in the pathogenesis of reperfusion injury and indicates that SOD1 
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may help maintain other antioxidant levels and prevent oxidative stress-induced injury and 
neuronal death after ischemia and reperfusion. Increased SOD1 levels and activity could also 
eliminate the formation of peroxynitrite since the lack of superoxide radicals to react with nitric 
oxide would prevent the generation of peroxynitrite.  
 An additional method by which SOD1 reduces the infarct volume and damage following 
ischemia is by the reduction of neuronal cell death. Studies have demonstrated that SOD1 
prevents the early release of cytrochrome c from mitochondria and inhibits the mitochondrial 
pathway of caspase activation [79,80]. SOD1 further inhibits neuronal cell death by increasing 
Akt phosphorylation and decreasing ERK1/2 phosphorylation [81,82]. Finally, SOD1 is 
indirectly involved in DNA repair by helping to maintain levels of the DNA repair protein Ape1 
following ischemia [83,84]. 
Ape1 and neuroprotection 
 Cells also utilize Ape1 as a means of neuroprotection under ischemic or hypoxic 
conditions. Studies in mice demonstrate that following ischemia, a decline in Ape1 expression 
occurs and this leads to increased DNA damage and cell death [83,85,86]. However, if Ape1 
expression is maintained or elevated, cell death, DNA damage, and cerebral infarct volume 
resulting from middle cerebral artery (MCA) occlusion are significantly reduced [84,87-89].  
Additional studies in which Ape1 was overexpressed in mice exposed to MCA occlusion 
demonstrate that infarct volume, DNA damage, and apoptosis are reduced compared to animals 
with normal Ape1 expression [87].  
 Both the DNA repair and redox functions of Ape1 are beneficial for its neuroprotective 
activities. In fact, not only does Ape1 recognize and repair apurinic sites that result from ROS, 
but it also enhances the activity of the enzyme which it follows in the base excision repair 
pathway, 8-oxoguanine-DNA glycosylase [48,90-92]. In this way, Ape1 increases the rate at 
which repair of oxidative lesions in DNA occurs.  
E2 and neuroprotection 
 Not only are antioxidants and proteins that maintain or repair macromolecules involved 
in neuroprotection, but 17β-estradiol (E2) is also known to mediate neuroprotective effects. Some 
of the best known work in this area is from studies by Wise and coworkers in which an MCA 
occlusion model was used to demonstrate that treatment of ovariectomized female rodents with 
physiological levels of E2 had significantly reduced levels of infarct damage and cell death [93-
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96]. However, neuroprotection was only observed when E2 was administered prior to artery 
occlusion [97]. Additional studies demonstrated that E2 protection occurred in estrogen receptor 
β (ERβ) but not in ERα null mice that have been subjected to MCA occlusion, indicating that 
ERα is necessary for E2-mediated neuroprotection [98,99]. Another group has determined that 
neuronal ERα is the cellular target of E2 in the brain [100]. Thus, E2 mediates it effects through 
neuronal ERα in the brain to limit ischemic damage in the cerebral cortex.  
 Menopause is characterized by the decreased production of ovarian hormones and this 
decline in hormones corresponds to an increase in stroke risk for women. Therefore, it has been 
suggested that this decline contributes to the increased stroke risk that women develop following 
menopause [93,101]. In fact, a woman’s risk of suffering a stroke doubles in the ten years 
following menopause [102,103]. From studies in rodents and humans, a “timing hypothesis” has 
been proposed and states that women achieve the greatest benefit from hormone replacement 
therapy when it is initiated during the menopausal transition or early postmenopause [104-107]. 
 The most compelling example of the importance of time between cessation of ovarian function 
and initiation of hormone replacement therapy is the Women’s Health Initiative. While initial studies 
were halted after invasive breast cancer was shown to be increased in the combined 
estrogen/progesterone arm of the study, further reanalysis revealed that when E2 replacement begins 
within ten years after the onset of menopause, women experience reduced rates of coronary heart disease 
and mortality [106,107]. 
 In addition to the influence of E2 on neural tissue, E2 has profound effects on uterine tissue 
[108,109]. For example, E2 regulates gene expression and influences cellular proliferation, remodeling, 
and angiogenesis in the uterus [110]. Not only are genes that are involved in endometrial remodeling 
regulated by E2, but oxidative stress response proteins are also altered by E2 treatment in the uterus [111] 
demonstrating that E2 differentially influences the expression of oxidative stress response proteins and 
emphasizes the need for selective estrogen receptor modulators that influence these and other 
antioxidant enzymes favorably in order to avoid detrimental repercussions.  
 Because of the constant ROS production by cellular metabolism, oxidative stress 
response proteins are essential in order to maintain cellular homeostasis, and this is especially 
important in the brain where metabolic activity is greatest. The contribution of even a single 
protein such as SOD1 demonstrates that a reduction in its expression or activity can have far-
reaching consequences including increased oxidative stress, protein damage, and ultimately 
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result in the development of a fatal disease state. Likewise, Ape1 is necessary to maintain protein 
and DNA integrity, a loss of which can lead to alteration of gene expression, DNA fragmentation, 
and cell death. Altogether, the impact of ERα and oxidative stress response proteins on cellular 
macromolecules and pathways demonstrates their necessity for the survival of cells, and their 
influence on human health and disease. 
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Figures and Figure Legends 
 
 
 
 
 
 
 
Fig. 1.1 Oxidative stress response proteins help maintain protein structure and function. Cu/Zn 
superoxide dismutase (SOD1) reduces superoxide (O2-) to hydrogen peroxide (H2O2) which is 
then converted to water by peroxiredoxins (Prx) and catalase (Cat). Reduced thioredoxin (Trx) 
activates Prx and thioredoxin reductase (TrxR) converts oxidized Trx to reduced Trx using 
NADPH as a cofactor. Trx, TrxR, apurinic endonuclease (Ape1), and protein disulfide isomerase 
(PDI) assist in converting oxidized zinc finger proteins to reduced proteins so they remain 
functional. 
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Fig. 1.2 The accumulation of superoxide leads to the formation of nitrotyrosine residues in 
proteins. When superoxide (O2-) accumulates it reacts with nitric oxide (NO) and can produce 
peroxynitrite (OONO-). Peroxynitrite nitrosylates tyrosine residues in proteins and can alter their 
structure and function. 
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CHAPTER TWO: 
Increased Oxidative Protein Damage in a Rodent Model of Amyotrophic Lateral Sclerosis 
 
Abstract 
Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that leads to 
paralysis and death within three to five years of the appearance of motor dysfunction. A common 
feature of sporadic and familial ALS is the formation of protein aggregates in spinal cord motor 
neurons. Although the underlying process involved in formation of these aggregates is not well 
understood, it has been suggested that oxidative damage to motor neurons may be involved in 
both forms of ALS. To better understand the process involved in protein aggregate formation, we 
examined spinal cord sections from transgenic mice that express wild type Cu/Zn superoxide 
dismutase 1 (WT SOD1) or a G85R SOD1 mutant protein, each of which is fused to yellow 
fluorescent protein.  We showed that protein damage and protein aggregate formation predated 
the onset of motor neuron dysfunction in transgenic mice that expressed the mutant G85R SOD1 
protein, but not in transgenic mice that expressed the WT SOD1 protein.  
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1. Introduction 
 Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the 
upper motor neurons in the cerebral cortex as well as the lower motor neurons of the brainstem 
and spinal cord [1,2]. Sporadic and inherited forms of this disease cause progressive atrophy of 
muscles and paralysis. Sporadic cases of ALS account for the majority of patients and are not 
associated with inherited genetic alterations [2]. Approximately 25% of patients have familial 
ALS which results from mutations in the oxidative stress response protein copper zinc 
superoxide dismutase (SOD1) [3,4].  
More than 160 mutations in SOD1 have been identified to date that lead to ALS [5], the 
large majority of which are missense substitutions scattered throughout the five exons of the 
gene. The majority of mutant SOD1-associated familial ALS is inherited in an autosomal 
dominant manner so that patients are typically heterozygous, expressing both the wild-type and 
mutant forms of SOD1 [2,6]. A common feature of both sporadic and familial ALS patients is 
the accumulation of insoluble protein aggregates [7] indicating that protein misfolding and 
aggregation are shared pathological features. Furthermore, sporadic and familial ALS are nearly 
indistinguishable clinically and pathologically [3,4], leading to the hope that strategies for 
treating familial ALS may translate to at least a subset of sporadic cases [8].  
It has been hypothesized that the misfolding of mutant SOD1 protein leads to formation 
of protein aggregates [2,4,6,9]. Wild-type SOD1 functions as a homodimer in which one copper 
and one zinc ion in each monomer are critical for its activity of converting superoxide to 
hydrogen peroxide. However some SOD1 mutations, such as those involved in coordinating the 
copper or zinc ion, render the enzyme nearly inactive [10]. When this occurs, superoxide 
accumulates in the cell and damage to macromolecules including DNA, lipids, and proteins can 
occur.  
Mutation of glycine at amino acid 85 to arginine, which is located in the metal binding 
region, causes a misfolded SOD1 mutant protein (G85R SOD1).  G85R SOD1 is associated with 
ALS in humans and causes motor neuron death and paralysis in transgenic mice [3,11,12]. 
Earlier studies indicated that free radical generation is increased in the presence of some SOD1 
mutants [13,14] and that oxidative damage is increased in familial and sporadic ALS patients 
[15]. To better understand the development of ALS and its progression, we examined effects of 
the G85R SOD1 mutation on oxidative protein damage by examining the expression and 
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localization of nitrosylated tyrosine residues, which have been used as an indicator of protein 
damage. 
2. Materials and Methods 
2.1. Transgenic mice 
 Transgenic mice were derived as described by Wang et al [12]. Briefly, a plasmid 
containing the human SOD1 gene [16] was modified to express the entire enhanced YFP gene 
(Clontech). A G85R mutation in exon IV of the SOD1 gene was introduced by oligonucleotide-
directed PCR mutagenesis of a restriction fragment, which was then substituted for the wild-type 
fragment. This fragment was sequenced to verify that only the desired nucleotide change was 
present. The final constructs were digested to produce DNA sequences that were injected into 
mouse embryos (C57BL/6J x SJL/J F2). Transgenic founder mice were identified by PCR 
amplification of DNA extracted from tail biopsies. Lines were maintained by periodic crossing 
with nontransgenic C57BL/6J x SJL/J F1 mice from Jackson Laboratory (Bar Harbor, ME). 
2.2. Immunofluorescent staining 
 20 µm spinal cord sections from 1, 2.5, or 5 month old G85R SOD1 mice and 3 month 
old WT SOD1 mice were obtained from Arthur Horwich (Yale University, New Haven, CT). 
The sections were dried at room temperature, dipped in PBS to remove O.C.T. compound 
(Sakura, Torrance, CA), post-fixed in 2% paraformaldehyde for 15 min, and washed 2x with 
PBS. 0.1% Trypsin-EDTA with 0.1% CaCl2 was used for antigen retrieval by incubating slides 
at 37°C for 30 min. Slides were then washed 2x with PBS, permeabilized in PBS with 0.5% 
Triton X-100 for 10 min, washed 2x with PBS, and incubated in blocking solution (PBS with 5% 
normal donkey serum and 0.1% Triton X-100) for 30-60 min. A nitrotyrosine-specific antibody 
(1:200, 06-284, Millipore, Billerica, MA), was diluted in blocking solution and incubated on 
slides for 2 h. Slides were washed 3x with PBS, incubated with DyLight 649-conjugated donkey 
anti-rabbit secondary antibody (1:500, Jackson ImmunoResearch Laboratories Inc., West Grove, 
PA) diluted in blocking solution for 1 h in the dark at room temperature, washed 3x with PBS, 
and stained with DAPI to identify nuclei. Lipofucsin-like autofluorescence was reduced by 
incubating slides in 50 mM ammonium acetate and 10 mM copper sulfate for 1 h. Slides were 
dipped in H2O then PBS and mounted with Pro-Long Gold antifade mounting media.  
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2.3. Image collection and quantitation 
All images were obtained either with a 10x objective or 40x oil-immersion objective 
using a Leica DM 4000 B confocal microscope and Leica TCS SPE system and Application 
Suite Advanced Fluorescence software (Leica Microsystems, Inc., Bannockburn, IL). Detector 
gain and offset, laser power, and bandwidth of emission collection were kept constant for all 
sections in each experiment and adjusted so that images had a full range of pixel intensities (0–
255) and saturation was minimized. Images from three independent experiments were collected 
to examine nitrotyrosylated proteins over time. 
Image Pro Plus software (Media Cybernetics, Bethesda, MD) was used for quantitative 
immunofluorescent analysis of nitrotyrosine staining in spinal cord sections. Analysis included 
10-32 fields in 5-10 spinal cord sections from 3 month old WT- and 1, 2.5 and 5 month old 
G85R SOD1-expressing mice. The perimeter and area were adjusted so that only specifically 
stained aggregates were detected and recorded in a script designed to analyze individual images 
in an entire z-stack. Data were exported into Excel and the mean area of specifically stained 
aggregates in each z-stack image was quantitated for each treatment. SAS 9.1 Basic Statistics 
(SAS Institute, Cary, NC) was used for statistical analysis. Data were combined and are 
presented as the mean ± SEM.  
3. Results 
3.1. SOD1 aggregation in disease progression 
 Immunofluorescent microscopy was used to examine the spinal cords of transgenic mice 
that expressed wild type (WT SOD1) or mutant (G85R SOD1) SOD1, each of which was fused 
to YFP, to examine formation of protein aggregates during disease progression. Accumulation of 
insoluble protein aggregates occurs in lower motor neurons within the anterior horn of the spinal 
cord [2,12]. The approximate location of the gray matter, where motor neurons reside, is outlined 
in a lumber spinal cord section from a WT SOD1 mouse (Fig. 2.1). At 3 months of age, low 
levels of SOD1 fluorescence were detected in WT SOD1 mice. By 1 month of age, SOD1 
protein aggregates were present in spinal cords from G85R SOD1 mice. At 2.5 months of age, 
the mutant G85R SOD1 aggregates were larger and more numerous. By 5 months, the spinal 
cords from G85R SOD1 mice had many smaller, less intense fluorescent aggregates scattered 
throughout the gray matter and even the surrounding white matter. 
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When visualized at higher magnification, SOD1 expression was nearly undetectable in 
WT SOD1 mice (Fig. 2.2A). In contrast, 1 month old G85R SOD1 mice had discrete aggregates. 
The aggregates were significantly larger in 2.5 month-old G85R SOD1 mice. At 5 months of age, 
the aggregates were diminished in size and fluorescent intensity. The same image collection 
settings were used for samples from WT and G85R SOD1 mice. 
3.2. Protein damage in disease progression 
SOD1 is the primary enzyme responsible for converting the free radical superoxide (O2•-) 
to less damaging hydrogen peroxide (H2O2) [17] (Fig. 2.2B). Other cellular enzymes then reduce 
hydrogen peroxide to water. When a mutation in the metal binding region occurs, such as G85R, 
SOD1 can no longer efficiently dismutate superoxide to hydrogen peroxide [11,12,18], which 
can lead to the accumulation of superoxide. Physiological levels of nitric oxide (NO•) react with 
excess superoxide to form the potent peroxynitrite (ONOO-) that is capable of nitrating protein 
tyrosine residues [4]. Nitrotyrosine can dramatically alter protein structure and function, leading 
to protein aggregation. 
In order to determine whether protein nitrosylation was increased in G85R SOD1 mice, 
spinal cord sections were stained using a nitrotyrosine-specific antibody to detect oxidative 
protein damage. As shown in Fig. 2.2C, no nitrotyrosine staining was observed in 3 month old 
mice that expressed WT SOD1. However nitrotyrosine staining was already apparent in 1 month 
old G85R SOD1 mice. Interestingly, the nitrotyrosine staining overlapped with the aggregated 
G85R SOD1. At 2.5 months, the nitrotyrosine staining increased as G85R SOD1 aggregates 
increased in size and number. At 5 months, nitrotyrosine staining was still observed although it 
was more dispersed, much like the G85R SOD1 protein.  
Image analysis software was used to quantitate the average area of the nitrotyrosine 
damage over time and indicated that at 1 month, G85R SOD1 mice had larger areas of protein 
damage than 3 month old WT SOD1 mice (Fig. 2.3D). There was a significant increase in the 
area of protein damage in 2.5 month old G85R SOD1 mice compared with transgenic mice that 
expressed WT SOD1 while the average area of damage decreased in 5 month old mice.  
4. Discussion 
 The formation of insoluble protein aggregates in spinal cord motor neurons is a hallmark 
of both sporadic and familial ALS and yet the underlying steps involved in the onset and 
progression of this disease are largely unknown. We have now shown that nitrotyrosine, an 
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indicator of oxidative protein damage, accumulates as disease progresses but then diminishes in 
area and fluorescence at the end stage of disease.  
 Our studies of G85R SOD1 transgenic mice have demonstrated that protein nitration was 
present in spinal cord motor neurons by 1 month of age and overlapped with G85R SOD1 
protein aggregation. Since nitration of even a single tyrosine residue can result in significant 
alterations in protein structure and function [4], it is likely that protein aggregation occurred 
following nitrotyrosine formation. Although G85R SOD1 mice did not exhibit motor symptoms 
at 1 month of age, insoluble SOD1 aggregates and nitrotyrosine protein damage were already 
obvious in the anterior horn of the spinal cord.  
By 2.5 months, the age when motor symptoms begin to appear (Maria Nagy, personal 
communication), protein aggregation and nitrotyrosine damage were widespread and abundant. 
The average area of oxidative protein damage significantly increased in 2.5 month old mice that 
expressed G85R SOD1 compared with mice that expressed WT SOD1. At 5 months, the age 
when paralysis occurred, protein aggregates and nitrotyrosine staining decreased in size and 
fluorescence intensity. This decreased aggregate size may have resulted from motor neuron cell 
death and release of their contents into the extracellular environment [6,19,20]. 
ALS in humans is often characterized by rapid disease progression in which paralysis and 
death occur within 3 to 5 years from the onset of symptoms [7,21]. Thus, by the time a patient 
presents with motor symptoms consistent with ALS, it is likely that spinal cord motor neurons 
already have extensive aggregates and oxidative protein damage. In fact, increased tyrosine 
nitration has been observed in spinal cord tissue from both sporadic and familial ALS patients 
[15], consistent with our findings of accumulated protein aggregation and nitrosylation in spinal 
cords of mice expressing G85R SOD1. 
Our studies demonstrate that aggregate formation and oxidative protein damage are early 
features of familial ALS that occur prior to the onset of motor symptoms. This work extends our 
understanding of the onset and progression of protein damage in familial ALS and may also 
inform us about the early events in sporadic ALS as well since the symptoms and pathology are 
so similar. Nitration of proteins at early stages of other neurodegenerative diseases has also been 
observed [4], indicating a possible common pathway of damage among diseases in which protein 
aggregation occurs.  
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Figures and Figure Legends 
 
 
 
 
 
 
Fig. 2.1 Low magnification view of spinal cord sections from transgenic mice expressing wild-
type or mutant SOD1. Immunofluorescence was used to detect YFP-tagged WT SOD1 or G85R 
SOD1. Spinal cords were harvested from mice at the indicated ages, sectioned with a cryostat, 
and imaged. Scale bars indicate 500 µm. 
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Fig. 2.2 High magnification view of spinal cord sections from transgenic mice expressing WT or 
mutant SOD1. (A) Immunofluorescent microscopy was used to detect YFP-tagged WT or G85R 
SOD1 from transgenic mice at the indicated ages. (B) During normal cellular metabolism SOD1 
converts superoxide (O2•-) to hydrogen peroxide (H2O2), which is then converted to water by 
other cellular enzymes. If superoxide accumulates, it can react with nitric oxide (NO•) to form 
peroxynitrite (ONOO-), which can in turn lead to nitration of tyrosine residues. (C) A 
nitrotyrosine-specific antibody and immunofluorescence were used to detect nitrosylated 
proteins. Scale bars indicate 25 µm. (D) Image analysis of nitrotyrosine staining area in spinal 
cord sections from WT SOD1 or G85R SOD1 transgenic mice at the indicated age. Data from 7-
22 images/animal were combined and are expressed as the mean area ± SEM. A significant 
increase in nitrotyrosine area occurred at 2.5 months compared with 3 month WT (*p < 0.05). 
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CHAPTER THREE: 
17β-Estradiol Increases Expression of the Oxidative Stress Response and DNA Repair 
Protein Apurinic Endonuclease (Ape1) in the Cerebral Cortex of Female Mice Following 
Hypoxia 
J. Steroid Biochem. Mol. Bio. (138) (2013) 410-420. 
 
Abstract 
While it is well established that 17β-estradiol (E2) protects the rodent brain from 
ischemia-induced damage, it has been unclear how this neuroprotective effect is mediated. 
Interestingly, convincing evidence has also demonstrated that maintaining or increasing the 
expression of the oxidative stress response and DNA repair protein apurinic endonuclease 1 
(Ape1) is instrumental in reducing ischemia-induced damage in the brain. Since E2 increases 
expression of the oxidative stress response proteins Cu/Zn superoxide dismutase and thioredoxin 
in the brain, we hypothesized that E2 may also increase Ape1 expression and that this E2-induced 
expression of Ape1 may help to mediate the neuroprotective effects of E2 in the brain. To test 
this hypothesis, we utilized three model systems including primary cortical neurons, brain slice 
cultures, and whole animals. Although estrogen receptor α and Ape1 were expressed in primary 
cortical neurons, E2 did not alter Ape1 expression in these cells. However, immunofluorescent 
staining and quantitative Western blot analysis demonstrated that estrogen receptor α and Ape1 
were expressed in the nuclei of cortical neurons in brain slice cultures and that E2 increased Ape1 
expression in the cerebral cortex of these cultures. Furthermore, Ape1 expression was increased 
and oxidative DNA damage was decreased in the cerebral cortices of ovariectomized female 
C57Bl/6J mice that had been treated with E2 and exposed to hypoxia. Taken together, our studies 
demonstrate that the neuronal microenvironment may be required for increased Ape1 expression 
and that E2 enhances expression of Ape1 and reduces oxidative DNA damage, which may in turn 
help to reduce ischemia-induced damage in the cerebral cortex and mediate the neuroprotective 
effects of E2. 
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1. Introduction 
 The human brain utilizes 20% of the oxygen consumed, but accounts for only 2% of total 
body mass, making it the most metabolically active organ in the human body [1]. Because 
reactive oxygen species (ROS) are produced as byproducts of normal cellular metabolism, the 
massive consumption of oxygen by the brain can lead to substantial ROS production. ROS play a 
role in cellular signaling such as MAP kinase activation and tyrosine phosphorylation [2-5]. 
However, if not effectively dissipated, ROS can accumulate and the ability of the cell to maintain 
a reduced intracellular environment is compromised, which can result in oxidative stress and 
damage to resident proteins, lipids, and DNA. 
 Cells rely on a variety of proteins to dissipate ROS, reduce oxidative stress, and, if 
damage does occur, to repair ROS-induced damage to cellular macromolecules. The oxidative 
stress response protein apurinic endonuclease (Ape1) is a multifunctional protein involved in 
DNA repair and redox regulation. Ape1 is the primary mammalian endonuclease and plays an 
essential role in repairing the most common DNA lesions, apurinic and 8-
hydroxydeoxyguanosine (8-OHG) sites [6-11]. In addition to its role in DNA repair, Ape1 is 
required for the reduction of oxidized cellular proteins and is especially important in maintaining 
numerous transcription factors in a reduced, active state [12-15].  Thus, Ape1 is required to 
maintain DNA integrity and protein structure and function in the brain. 
 Ape1 is also instrumental in repairing cellular damage caused after blood vessel 
occlusion as might occur during a stroke [16-18]. While the hypoxia resulting from blood vessel 
occlusion is deleterious, reoxygenation can be even more damaging as the oxygen supply is 
reestablished and ROS production rapidly escalates [19-21]. Studies in rodents have 
demonstrated that Ape1 levels decline following middle cerebral artery (MCA) occlusion leading 
to DNA damage and cell death in the infarct region [16,22,23].  However, by simply maintaining 
Ape1 levels, cell death and DNA damage can be reduced [16,17]. Furthermore, if Ape1 is 
overexpressed, DNA damage and cerebral infarct volume resulting from MCA occlusion is 
significantly reduced [18].   
 While best known for its role in female fertility, the steroid hormone 17β-estradiol (E2) 
also alters the expression of proteins involved in oxidative stress response, anti-inflammatory 
processes, and programmed cell death in the brain [24-35]. A number of laboratories have 
demonstrated that E2 diminishes neuronal injury associated with cerebral ischemia and brain 
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trauma in rodents [36-40].  This E2-induced neuroprotection is most apparent in the cerebral 
cortex, which is particularly vulnerable to ischemia-induced injury [17,18,24-27,41]. An elegant 
series of studies by Wise and coworkers demonstrated that exposing ovariectomized female 
rodents to physiological levels of E2 reduces the infarct volume and cell death that occurs 
following MCA occlusion [24-27], but that this neuroprotective effect was only observed when 
the E2 was administered prior to artery occlusion [28]. Furthermore, the fact that E2 pretreatment 
decreases infarct volume in estrogen receptor β (ERβ), but not in estrogen receptor α (ERα) null 
mice that have been subjected to MCA occlusion, demonstrates that ERα, not ERβ, is involved in 
this E2-mediated neuroprotection [29,30].  
We previously demonstrated that E2 increases expression of the oxidative stress response 
protein Cu/Zn superoxide dismutase in brain slice cultures and that this E2-induced expression 
helps to limit protein and DNA damage of cerebral cortical neurons [42].  From these studies we 
hypothesized that E2 might also increase Ape1 expression in the brain and that this E2-induced 
expression of Ape1 could help to protect the cerebral cortex from hypoxia-induced cell damage. 
2. Materials and Methods 
2.1. Mice 
 C57BL/6J breeding pairs for the generation of mouse pups for isolation of primary 
cortical neurons and brain slice cultures and female mice (12-15 weeks) were obtained from 
Jackson Laboratory (Bar Harbor, ME). All mice were maintained on a 12 h light/dark schedule 
with access to water and food ad libitum. Ovariectomized mice were maintained on 
phytoestrogen-free chow. Primary cortical neurons were prepared from P0 female mouse pups, 
non-neuronal cultures for the preparation of conditioned media were prepared from P0-P3 female 
mouse pups, and brain slice cultures were prepared from P7 to P9 day old female pups. Female 
pups were identified by the smaller anogenital distance and the absence of an adjacent pigmented 
region. All procedures were performed in accordance with guidelines of the University of Illinois 
at Urbana-Champaign Institutional Animal Care and Use Committee and Division of Animal 
Resources.  
2.2. Primary cortical neurons 
The isolation of primary cortical neurons was performed as described [43] with the 
following modifications. Conditioned plating medium (Neurobasal-A with 0.5 mM GlutaMAX, 
B27 supplement without antioxidants [Life Technologies, Grand Island, NY], and antibiotics) 
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and conditioned maintenance medium (Neurobasal-A with 0.5 mM GlutaMAX, custom-
formulated media supplement [Table 1], and antibiotics) were prepared by incubating non-
neuronal cultures with media for 24 h. Cortical pieces were triturated in conditioned plating 
media, cells were counted and seeded on poly-D-lysine coated 60 mm petri dishes at 115,000 
cells/cm2 or on poly-D-lysine and fibronectin pre-coated German glass coverslips (EMS, 
Hatfield, PA) at 50,000 cells/cm2. Neurons were incubated overnight and the conditioned plating 
media was removed and replaced with conditioned maintenance media. Primary cortical neurons 
were treated with 1 µM cytosine ß-D-arabinofuranoside once a week to reduce glial cell 
proliferation. Media was removed from the primary cortical neurons and replaced with 
conditioned maintenance media twice a week. Ethanol or 20 nM E2 was added 24 h prior to cell 
harvest. All cells were maintained in a 5% CO2 incubator at 36°C.  
2.3. Brain slice cultures  
Brain slice cultures were prepared essentially as described [44] with modifications. Pups 
were decapitated and whole brains were quickly removed, mounted, and sectioned with a Leica 
VT1200 vibratome (Leica Microsystems, Nussloch, Germany). 300 µm coronal sections were 
sliced into chilled slicing solution (1.25 mM NaH2PO4, 2.5 mM KCl, 10 mM MgSO4, 0.5 mM 
CaCl2, 234 mM sucrose, 11 mM glucose and 26 mM NaHCO3). Slices were immediately placed 
on a sterile Millicell culture plate insert (Millipore, Billerica, MA) in each well of a chilled 12-
well plate. Excess slicing solution was removed following sectioning and replaced with 1.2 ml of 
Neurobasal-A medium (Gibco, Carlsbad, CA) containing 0.5 mM GlutaMAX (Gibco), 
antibiotics (penicillin, streptomycin, and gentamycin) and 10% charcoal dextran-treated fetal 
bovine serum with ethanol or 20 nM E2. Slices were maintained in a 5% CO2 incubator at 36 °C 
for 24 h.  
2.4. Ovariectomy  
12-15 week old female mice were anesthetized by inhalation of 4% isoflurane, bilaterally 
ovariectomized, and implanted subcutaneously with silastic tubing (0.062 in/0.125 in, inner/outer 
diameter, 1 in length; Dow Corning, Midland, MI) plugged at both ends with medical adhesive 
(Dow Corning). Tubing contained 35 µl cottonseed oil (vehicle) or 35 µl of 180 µg/ml E2 in 
cottonseed oil, which produces a low physiological level of circulating E2 (~25 pg/ml) [29] that 
is equivalent to estrous levels of E2 in mice [45-47].  
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2.5. Hypoxia treatment  
7 days after ovariectomy and implantation of silastic tubing, oil- and E2-treated mice 
were placed in cages inside a hypoxia chamber (BioSpherix, Lacona, NY) that was equilibrated 
to 7% O2 and 93% N2 for 3 h, conditions which have been shown to induce substantial changes 
in mRNA expression [48]. Oxygen concentration was monitored continuously throughout the 
experiments. Oil- and E2-treated mice were also maintained at normoxic conditions for 3 h. After 
hypoxia, animals were allowed to reoxygenate for 1 h (RT-PCR) or 3 h (protein expression and 
DNA damage). Following hypoxia and re-oxygenation, all animals were anesthetized with 
isoflurane, decapitated, and cerebral cortices were harvested for quantitative real time-PCR, 
immunofluorescent staining, Western blot, or DNA damage analyses.  
2.6. Western blot analysis  
Primary neurons, brain slice cultures, or cerebral cortical hemispheres were combined 
with 400, 250, or 800 µl RIPA buffer (Thermo Scientific, Rockford, IL), respectively, with 1x 
Protease Inhibitor Cocktail (Sigma) and homogenized for 10 seconds at high speed with a Pro 
Homogenizer (ProScientific Inc., Oxford, CT). The buffer was adjusted to 400 mM NaCl with 5 
M NaCl, placed on ice, and vortexed every 5 min for 15 min. The extract was spun at 20,800 x g 
in a 4°C microfuge, the supernatant was removed, and protein assays were performed with 
bicinchoninic acid using BSA as the protein standard (Thermo Scientific). Whole cell lysates (25 
µg) were loaded onto each lane of a denaturing gel and fractionated. Proteins were transferred to 
a nitrocellulose membrane and blots were probed with an Ape1- (1:2000, ab194, Abcam Inc., 
Cambridge, MA), β-tubulin- (1:5000, sc9104, Santa Cruz Biotechnologies, Santa Cruz, CA) or 
α-tubulin- (1:100,000, T6199, Sigma) specific antibody followed by a secondary antibody 
covalently linked to infrared fluorophores (IRDye 800CW donkey anti-mouse IgG [1:5,000, LI-
COR Biosciences, Lincoln, NE] or IRDye 800CW donkey anti-rabbit IgG [1:5,000, LI-COR 
Biosciences]). The membranes were scanned with an Odyssey infrared imager (LI-COR 
Biosciences) to quantitate the level of protein present. The integrated intensity function with the 
automated median background correction method was used since this system provides a wide 
dynamic range and reduces error to improve quantitative accuracy [49,50].  
2.7. Immunofluorescence imaging 
Brain slices from cultures and whole animals were rinsed 2x with PBS, fixed in PBS with 
4% formaldehyde for 1 h, washed 3x with PBS, permeabilized with PBS containing 1% Triton 
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X-100 for 30 min, and incubated in blocking solution (PBS with 0.05% Tween-20 and 5% 
normal donkey serum) for 1–2 h. Slices were then incubated in blocking solution with an ERα-, 
(1:600, ab31312, Abcam Inc.), Ape1- (1:100, sc9919, Santa Cruz Biotechnologies), or NeuN- 
(1:500, MAB377, Millipore, Temecula, CA) specific antibody for 2 h at room temperature. 
Slices were washed 3x with PBS containing 0.1% Tween-20 (PBS-T) and incubated with 
DyLight 549-, 649- or 488-conjugated anti-rabbit, anti-goat or anti-mouse IgG (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA), respectively, for 1 h in the dark at room 
temperature, washed 3x with PBS-T, incubated with DAPI nucleic acid stain for 30 min at room 
temperature, washed 3x with PBS, and mounted with Pro-Long Gold antifade reagent (Life 
Technologies). 4′,6-diamidino-2-phenylindole (DAPI) co-staining was included with each 
treatment to identify nuclei and ensure that similar numbers of cells were present. Control slices, 
which had not been exposed to primary antibody, were processed in parallel.  
Primary cortical neurons were stained as described for the brain slices with the following 
modifications. After primary neurons were rinsed 2x with PBS, they were fixed in PBS with 4% 
formaldehyde for 15 min, washed 3x with PBS, permeabilized with PBS containing 0.5% Triton 
X-100 for 10 min, and incubated in blocking solution for 30 min. DAPI staining time was 
reduced to 10 min.  
2.8. Image collection and quantitation 
All images were obtained with a 40x oil-immersion objective using the Leica DM 4000 B 
confocal microscope and Leica TCS SPE system and Application Suite Advanced Fluorescence 
software (Leica Microsystems, Inc., Bannockburn, IL). Detector gain and offset, laser power, 
and bandwidth of emission collection were kept constant for all treatments in each experiment 
and adjusted so that images had a full range of pixel intensities (0–255) and saturation was 
minimized. Images from 8 independent experiments were collected from primary cortical 
neurons to examine effect of E2 on Ape1 expression.  
Image Pro Plus software (Media Cybernetics, Bethesda, MD) was used for quantitative 
immunofluorescent analysis of Ape1 staining in brain slice cultures. Analysis included 477 
(ethanol) or 742 (E2) z-stack images from 6 (ethanol) or 7 (E2) individual brain slice cultures. 
The perimeter and area were adjusted so that only specifically stained cells were detected and 
recorded in a script designed to analyze the individual images in an entire z-stack. Data were 
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exported into Excel and the mean density/intensity of specifically stained cells in each z-stack 
image was quantitated for each treatment.  
2.9. RT-PCR 
 Total RNA was isolated from mouse cortices using RNAqueous reagents (Ambion, Life 
Technologies, Austin, TX) according to the manufacturer’s instructions. RNA concentrations 
were measured and cDNA was synthesized using the iScript kit (Bio-Rad, Hercules, CA) as 
described by the manufacturer. 1µl of cDNA was combined with iQ SYBR Green Supermix 
(Bio-Rad, Hercules, CA), forward and reverse primers for HIF3α (5’- 
GGACTCAGACTCAGGCTACAG-3’ and 5’- TCAGGAAGTGGACGCAGATG-3’) and 
VefgA (5’- GGCTGCTGTAACGATGAAG-3’ and 5’- TCTGCTGTGCTGTAGGAAG-3’) and 
real-time PCR was carried out using a Bio-Rad iQ5 multicolor Real-Time PCR Detection 
System. Standard curves were created using cDNA equivalents of 0.125, 1.25 and 12.5 ng of 
RNA and were run in triplicate with each primer set for each experiment.  
2.10. 8-hydroxydeoxyguanosine quantitation 
 Genomic DNA was isolated by digesting each cerebral cortex in 500 µl of DNA isolation 
buffer (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 25 mM EDTA, pH 8.0, 0.5% SDS, 1 mg/ml 
proteinase K [Sigma], 200 µg/ml RNase A [Sigma]) overnight at 50°C in a rotating incubator. 
After tissue digestion, 500 µL of phenol-chloroform-isoamyl alcohol (25:24:1) was added and 
samples were vortexed and centrifuged at 15,000 x g for 5 min at room temperature. The top, 
aqueous phase was transferred to a fresh tube. DNA was precipitated, resuspended in Tris-EDTA 
and 8- hydroxydeoxyguanosine (8-OHG) oxidative DNA damage was quantitated using the 
OxiSelect Oxidative DNA Damage ELISA kit (Cell Biolabs, San Diego, CA). A 96 well plate 
was coated with 8-OHG conjugate overnight. Sample DNA was denatured, digested, and treated 
with alkaline phosphatase. Individual samples or 8-OHG standards were added to the coated 
plate and 8-OHG antibody was added to each well for 1 hr. Wells were rinsed with wash buffer 
3x and secondary antibody was added. After 1 hr, wells were washed 3x and the substrate 
solution was added. Stop solution was added to each well after the color had developed and the 
absorbance was read at 450 nm using a SpectraMax Plus 384 plate reader. 
2.11. Statistics 
Combined data are expressed as the mean ± SEM. SAS version 9.2 (SAS Institute Inc., 
Cary, NC) was used for statistical analysis. Ape1 protein expression in brain slice cultures was 
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analyzed using Student’s t-test. Statistical analyses of HIF3α and VegfA mRNA expression, 
Ape1 protein expression, and 8-OHG levels among all groups of animals were compared using a 
two-way analysis of variance (ANOVA). A p value of <0.05 was considered statistically 
significant (95% confidence interval).  
3. Results 
3.1. Ape1 expression in primary cortical neurons 
Since neuronal ERα is essential for E2-mediated neuroprotection [29,30,36] and the 
cerebral cortex is particularly susceptible to ischemia-induced damage [17,18,24-27,41], we 
examined the expression of ERα and Ape1 in primary cultures of cortical neurons. Primary 
neurons were isolated from the cerebral cortices of newborn C57Bl/6J female mouse pups and 
cultured for 9 or 10 days in vitro. When an ERα antibody was preincubated with purified ERα 
and used in immunofluorescence assays, no staining was detected (data not shown).  In contrast, 
antibody that had not been preincubated with receptor detected robust ERα staining, thus 
confirming the specificity of the antibody (Fig. 3.1A). Quantitative real-time PCR demonstrated 
that ERα transcripts were present in primary neurons that had been cultured for 9 days (data not 
shown). Furthermore, immunofluorescent staining demonstrated that the expression of Ape1 was 
quite robust in these cells as well suggesting that they might be an appropriate model system to 
study the potential effects of E2 on Ape1 expression.   
When primary cerebral cortical neurons were treated with ethanol vehicle or 20 nM E2 for 
24 h, no changes in Ape1 expression were detected using Western blot (Fig. 3.1B) or 
immunofluorescence (Fig. 3.1C) analyses. Ape1 staining was confined to the nuclear 
compartment of the primary neurons (Fig. 3.1C, compare Ape1 and NeuN staining). Varying the 
concentration (10-100 nM) or time (3-48 h) of E2 treatment did not alter Ape1 expression (data 
not shown). Even after eliminating the superoxide dismutase, catalase, corticosterone, and 
progesterone from the B27 media supplement, which are typically used for primary neuronal 
cultures (Table 1), we were still unable to detect an E2-induced expression of Ape1. Thus, in 
spite of the fact that ERα was present and would presumably have been able to respond to E2 
treatment, no changes in Ape1 expression were observed suggesting that the primary neurons 
may require other cell types and/or the organizational features and structural architecture present 
in the intact brain.  
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3.2. Ape1 expression in brain slice cultures 
To more closely recapitulate the neuronal environment present in the brain, we used brain 
slice cultures, which maintain much of the spatial architecture and many of the organizational 
features and local synaptic connections present in the brain [44].  Since the cellular environment 
can be carefully defined and manipulated, brain slice cultures have been used extensively to 
study electrophysiological properties, angiogenesis, dendritic growth, neural cell migration, and 
the responsiveness of neural cells to various drugs and treatments including E2  [42,51-55].  
Brain slice cultures were prepared from 7-9 day old C57Bl/6J mouse pups. 
Immunofluorescent staining was used to characterize the expression of Ape1 and ERα in the 
cerebral cortex. In order to decrease variation and limit bias, the same regions of the cerebral 
cortex (Fig. 3.2A, red boxed regions) were examined in each of the experiments described 
herein. Ape1 was expressed in the nuclei of cerebral cortical neurons as shown by co-staining 
with DAPI and the neuronal marker NeuN (Fig. 3.2B and C). Similarly, ERα was expressed in 
the nuclei of cerebral cortical neurons (Fig. 3.2D). In contrast, no staining was observed when 
the Ape1- or ERα-specific antibody was omitted (data not shown). The co-expression of ERα 
and Ape1 in the nuclei of the same cerebral cortical neurons was evident when the ERα and 
Ape1 channels were merged (Fig. 3.2E). 
When brain slice cultures were treated with ethanol or 20 nM E2 for 24 h and stained with 
an Ape1-specific antibody, Ape1 staining was observed in the absence of E2, but when brain 
slice cultures were treated with E2, Ape1 staining was increased (Fig. 3.3A). 
Immunofluorescence image analysis of ethanol- or E2-treated brain slice cultures demonstrated 
that Ape1 expression was significantly increased in the cerebral cortex when cultures were 
treated with E2 compared to cultures that were treated with ethanol vehicle (Fig. 3.3B).   
Whole cell extracts were prepared from brain slice cultures that had been treated with 
ethanol or 20 nM E2 for 24 h and Western blot analysis was performed to examine the effect of 
E2 on Ape1 expression using another independent method (Fig. 3.3C). Combined data from 8 
individual brain slice cultures demonstrated that E2 significantly increased Ape1 expression (Fig. 
3.3D). These findings confirmed that E2 increased Ape1 expression in cortical neurons and 
demonstrated that brain slice cultures provide a valuable model system to study estrogen action 
in the brain. 
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3.3. Effect of hypoxia on Ape1 expression and DNA damage in the cerebral cortex of mice 
Previous studies have demonstrated that significantly less neural damage is observed 
when ovariectomized female rodents are treated with E2 and subjected to MCA occlusion than 
when animals have been treated with oil [24-27]. Thus, MCA occlusion experiments have been 
extremely informative in demonstrating the neuroprotective effects of E2.  However, because the 
infarct region contains dead or dying cells using this experimental paradigm, the amount of 
information that can be gathered from these cells is limited. Thus, rather than use an artery 
occlusion method, we examined the effect of hypoxia, a hallmark of ischemia, in ovariectomized 
female mice that had or had not been treated with E2.  
C57Bl/6J female mice were ovariectomized and silastic tubing containing oil or E2 was 
implanted.  After 7 days, a time when E2-mediated neuroprotection is observed in rodents 
[25,28-30,56,57], mice were placed in a hypoxia chamber that was equilibrated to 7% oxygen to 
mimic the decrease in oxygen that can occur with ischemia.  The animals were allowed to 
recover in normoxic conditions and then sacrificed. Control mice that had not been exposed to 
hypoxia were processed in parallel.  
Previous studies have shown that hypoxia induces the expression of several genes in the 
brain including HIF3α and VegfA [58-62]. Quantitative real-time PCR demonstrated that when 
animals were exposed to hypoxia for 3 h and allowed to recover for 1 h, HIF3α and VegfA 
transcript levels were significantly increased (Figs. 3.4A and B, respectively).  
Immunofluorescent staining of the cerebral cortex from ovariectomized female mice that 
had been treated with oil or E2 for 7 days, exposed to hypoxia for 3 h, and allowed to recover to 
normoxic conditions for 3 h indicated that Ape1 (Fig. 3.5A) and ERα (Fig. 3.5B) were present in 
the nuclei of the cerebral cortical neurons. Whole cell extracts were prepared from cerebral 
cortices to determine whether E2 altered Ape1 expression during hypoxia using Western blot 
analysis (Fig. 3.6A). As seen in Fig. 3.6B, a modest but significant increase in Ape1 expression 
was observed when mice were treated with E2 and exposed to hypoxia.  Thus, E2 treatment and 
hypoxia together increased Ape1 expression in the cerebral cortex of ovariectomized female 
mice.  
Guanine is particularly susceptible to oxidation and is the most common target of 
oxidative DNA damage. 8-hydroxydeoxyguanosine (8-OHG) mispairs with adenine and results 
in a guanine to thymine transversion and perturbation in DNA conformation [63].  To determine 
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whether E2 altered DNA damage during hypoxia, the level of 8-OHG was examined. 
Ovariectomized female mice were treated with oil or E2 for 7 days, exposed to hypoxia for 3 h, 
recovered at normoxic conditions for 3 h, and then sacrificed. Control mice that had not been 
exposed to hypoxia were processed in parallel. Genomic DNA was isolated from cerebral 
cortices and 8-OHG levels was measured and reported as the normalized mean ± SEM (Fig. 
3.6C). E2 significantly reduced 8-OHG levels in the cerebral cortex of mice that had been 
exposed to hypoxia. 
4. Discussion 
 Although it has been known for some time that E2 decreases ischemia-induced damage in 
the rodent brain, the mechanisms mediating this neuroprotective effect have remained unclear 
[24-27]. We now provide evidence for a link between E2 treatment, Ape1 expression, and 
neuroprotection. Our studies demonstrate that E2 increased Ape1 expression in the cerebral 
cortex of brain slice cultures and that combined hypoxia and E2 treatment increased Ape1 
expression and decreased 8-OHG oxidative DNA damage in the mouse cerebral cortex. 
4.1. Ape1-induced neuroprotection 
 Previous studies have convincingly demonstrated that Ape1 protects the brain from 
ischemia-induced injury by decreasing DNA damage and cell death [16-18,22,23]. One way 
Ape1 might protect the cerebral cortex from ischemia-induced damage is by repairing DNA. In 
fact, results from our studies demonstrate that when E2 was administered prior to a hypoxic event, 
the levels of the oxidative DNA damage marker 8-OHG were significantly decreased.  
Ape1 is an essential enzyme in the base excision repair pathway. Ape1 recognizes and 
repairs apurinic sites and also enhances the activity of 8-oxoguanine-DNA glycosylase, the 
enzyme responsible for removing 8-OHG lesions [6,9-11]. Furthermore, Ape1 activity in base 
excision repair is especially vital in post-mitotic cells such as neurons that rely predominantly on 
this pathway to maintain DNA integrity [64-66]. When Ape1 expression declines after MCA 
occlusion, extensive DNA and cellular damage is observed [16,17]. However, if Ape1 expression 
is maintained or elevated, the number of DNA lesions significantly decline [17,18,67,68]. Our 
work demonstrates that even the modest elevation of Ape1 protein expression observed in mice 
that had been treated with E2 and then exposed to hypoxia is sufficient to decrease oxidative 
DNA damage. Thus, the E2-induced increase in Ape1 expression may help to protect the cerebral 
cortex from ischemia-induced DNA damage. 
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Another mechanism by which Ape1 can reduce ischemic injury is by maintaining 
numerous proteins in an active, reduced state. When ROS accumulate, cellular proteins can 
become oxidized and are no longer functional. Ape1 reduces a number of transcription factors 
including p53, NFκB, Fos, Jun, and HIF1α [12-15].  The ability of these transcription factors to 
modulate expression of numerous genes could have widespread effects on gene expression, 
cellular function, and neuronal survival [7,69]. Thus, Ape1 is required to maintain protein 
structure and function and preserve cellular homeostasis that is critical in the central nervous 
system. The overall importance of Ape1 is evident in the embryonic death of Ape1 null mice 
[70,71]. 
4.2. Combined data from the three models 
 At first glance the findings from our cell-based, brain slice, and whole animal studies 
may seem inconsistent. However, a more careful inspection highlights the fact that each model 
system provides clues about the requirements for Ape1 expression in the cerebral cortex.  The 
fact that no increase in Ape1 expression was observed in primary cortical neurons seems 
contradictory to the brain slice and whole animal studies where E2 increased Ape1 expression. 
However, it seems plausible that the failure of E2 to alter Ape1 expression in primary neurons 
might be attributed to the lack of architectural and organizational features present in the brain 
microenvironment and/or the absence of other cells such as astroglia, microglia, or 
oligodendrocytes.  Recently, E2 has been shown to increase glial cell release of growth factors 
that promote neuronal survival [72]. The presence of these other cells and/or organizational 
features in the brain slice cultures may be required for E2-induced expression of Ape1 as 
observed in the brain slice cultures. When the neuronal environment was more closely 
recapitulated in brain slice cultures, E2 treatment was sufficient to enhance Ape1 expression. 
However, both hypoxia and E2 treatment were required for increased Ape1 expression in the 
whole animal. If one considers that brain slice cultures are exposed to significant stress during 
harvesting and slicing, this stress combined with E2 treatment may be sufficient to increase Ape1 
expression in brain slice cultures and supports the idea that E2 alone may not be sufficient to 
increase Ape1 expression.  
4.3. Role of E2-induced proteins in neuroprotection 
Although our studies focused on the E2-induced expression of a single oxidative stress 
response protein, Ape1, E2 enhances the expression of other oxidative stress response proteins 
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including Cu/Zn superoxide dismutase and thioredoxin, which are known to reduce ischemia-
induced damage [42,73-75]. Superoxide dismutase reduces superoxide levels and decreases 
protein and DNA damage in neurons [42]. Thioredoxin, like Ape1, reduces oxidized cellular 
proteins and enhances ischemia-induced neuronal survival [76,77]. Overexpression of Ape1, 
Cu/Zn superoxide dismutase, or thioredoxin confers a neuroprotective effect following MCA 
occlusion [18,77,78]. Furthermore, intravenous administration of thioredoxin in mice following 
ischemia reduces infarct volume, protein damage, and cell death [79]. Together these studies 
emphasize the important role that oxidative stress response proteins have, as a whole, in 
sustaining cell viability after an ischemic event [16,17,23,77].  
Although an E2-mediated increase in Bcl-2 expression has also been implicated in 
inhibiting apoptosis after an ischemic event [34,35], it seems unlikely that simply limiting 
apoptosis in neurons with extensive DNA damage would be beneficial. However, if the E2-
mediated increase in Bcl-2 expression was coupled with increased expression of oxidative stress 
response and DNA repair proteins, together these proteins could reduce protein and DNA 
damage and enhance neuronal cell survival.  
In addition to reducing oxidative stress and apoptosis by mediating the induction of 
oxidative stress response proteins and Bcl-2 in the brain, E2 attenuates inflammation by reducing 
pro-inflammatory molecules, decreases cytokine and chemokine release following administration 
of a neuroinflammatory endotoxin, and reduces microglial activation and peripheral monocyte 
recruitment [31-33]. 
While it is clear that ERα plays a role in E2-mediated neuroprotection [29,30], other 
studies have implicated a role for ERβ in neuroprotection [80]. Both ERα and ERβ are involved 
in E2-mediated neurogenesis in the subventricular zone, which generates neural stem cells that 
migrate to the site of injury [81].  In addition, estrogen binding sites in the mitochondria and 
plasma membranes have also been implicated in conferring estrogen responsiveness [82,83]. 
4.4. Biological relevance of E2-induced Ape1 expression 
 The protective effects of E2 have been documented in numerous animal studies but have 
also been reported in humans as well [24-30,84,85]. It has been suggested that the decline in 
production of ovarian hormones contributes to the increased incidence of stroke in 
postmenopausal women [24,86]. In fact, a number of observational and epidemiological studies 
have reported that E2 replacement therapy in postmenopausal women reduces stroke as well as 
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coronary heart disease and neurodegenerative diseases [87-93]. Importantly, recent analysis of 
data from the Women’s Health Initiative indicates that women who initiate E2 replacement 
therapy before 60 years of age or within ten years of menopause have reduced rates of coronary 
heart disease and mortality [84,85]. 
Taken together, our studies demonstrate that E2 treatment increases Ape1 expression in 
the cerebral cortex and suggest that E2 mediates its neuroprotective effects in the brain in part by 
increasing expression of oxidative stress response proteins and reducing oxidative DNA damage. 
Because the maintenance or overexpression of Ape1 results in decreased ischemia-induced 
damage [16-18] and the decline of Ape1 expression leads to an increase in ischemic damage 
[16,22,23], we believe that the E2-mediated increase in Ape1 expression enables neurons to 
repair DNA lesions, reduce oxidized cellular proteins, and more effectively regulate 
transcription.  
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Figures and Figure Legends 
 
 
 
 
 
 
Fig. 3.1 Ape1 and ERα are expressed in primary cortical neurons. Cerebral cortical neurons were 
isolated from P0 mouse pups and cultured in vitro for 10 days. (A) Immunofluorescent staining 
was performed using ERα- and Ape1-specific antibodies. Neurons were treated with ethanol or 
20 nM E2 for 24 h and whole cell extracts were prepared for (B) Western blot analysis using 
Ape1- and α-tubulin-specific antibodies or (C) immunofluorescent staining using Ape1- and 
NeuN-specific antibodies. Scale bars indicate 25 µm. 
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Fig. 3.2 Ape1 and ERα are expressed in cortical neurons in brain slice cultures. (A) Red boxes 
indicate the regions of the cerebral cortex examined by immunofluorescence. Immunofluorescent 
staining was performed with brain slice cultures using (B) DAPI to identify cortical cell nuclei, 
(C) Ape1- and NeuN-, (D) ERα- and NeuN-, or (E) Ape1- and ERα-specific antibodies. Scale 
bar indicates 25 µm.  
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Fig. 3.3 E2 increases Ape1 expression in brain slice cultures. Brain slice cultures were treated 
with ethanol or 20nM E2 for 24 h. (A) Immunofluorescent staining was performed using an 
Ape1-specific antibody. DAPI staining was included to identify cortical cell nuclei. Scale bar 
indicates 25 µm. (B) Image analysis of Ape1 expression from 6 individual ethanol- or 7 
individual E2-treated brain slice cultures were combined and are expressed as the mean 
density/intensity ± SEM. (C) Whole cell extracts from brain slice cultures were prepared and 
quantitative Western blot analysis was performed using Ape1- and β-tubulin-specific antibodies. 
Ape1 expression was normalized to β-tubulin expression. (D) Data from 8 individual brain slice 
cultures were combined and are expressed as the normalized expression ± SEM. Ape1 
expression from ethanol- or E2-treated brain slice cultures were compared using Student’s t test 
to determine statistical significance (* p < 0.05, ** p < 0.001). 
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Fig. 3.4 Hypoxia significantly increases HIF3α and VegfA transcript levels. Ovariectomized 
female mice were treated with oil or E2 for 7 days and subjected to normoxic or hypoxic 
conditions. Cortices were dissected and total RNA was isolated. cDNA was synthesized and 
quantitative real-time PCR was carried out with (A) HIF3α- or (B) VegfA-specific primers. The 
relative fold change was calculated using the delta-delta Ct method with ribosomal protein L7 
(RPL7) as a control. The mean relative fold change in each group is shown ± SEM. Two-way 
analysis of variance (ANOVA) was used to detect a significant difference in mRNA levels from 
mice that had been exposed to hypoxia compared with mice that had been exposed to normoxia 
(* p < 0.0001). The number of animals in each treatment group is indicated at the base of each 
bar. 
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Fig. 3.5 E2 increases Ape1 expression after hypoxia in the mouse cerebral cortex. 
Ovariectomized female mice were treated with oil or E2 for 7 days, subjected to normoxic or 
hypoxic conditions, and allowed to recover for 3h. Immunofluorescent staining was performed 
using an (A) Ape1- or (B) ERα-specific antibody. DAPI staining is shown in the inserts. Scale 
bars indicate 25 µm. 
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Fig. 3.6 E2 and hypoxia increase Ape1 protein expression and decrease 8-OHG damage in the 
mouse cerebral cortex. Ovariectomized female mice were treated with oil or E2 for 7 days and 
subjected to hypoxic conditions. (A) Quantitative Western blot analysis using whole cell extracts 
from cerebral cortices was performed using Ape1- and α-tubulin-specific antibodies. (B) Ape1 
expression was normalized to α-tubulin expression and data are expressed as the relative fold 
change ± SEM. The value above each band indicates the relative fold change for each condition. 
(C) Genomic DNA was isolated from each cerebral cortex and 8-OHG concentrations were 
measured. Data represent the normalized mean ± SEM. Two-way analysis of variance (ANOVA) 
was used to detect significant differences in Ape1 protein expression or 8-OHG level in response 
to hypoxia (* p < 0.05) or E2 (# p < 0.05). Relative fold change on the Y-axis indicates the 
normalized mean value for each treatment with the value of oil-treated mice maintained at 
normoxic conditions set at 1. The number of animals in each treatment group is indicated at the 
base of each bar. 
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CHAPTER FOUR: 
Estrogen Receptor α Protein Expression in the Cerebral Cortex 
In preparation 
 
Abstract 
Although estrogen receptor alpha (ERα) and 17β-estradiol play critical roles in target 
tissues, little is known about the expression of ERα in the cerebral cortex. We have examined 
ERα mRNA and protein levels in the cerebral cortex of female mice at postnatal days 5 and 17 
and at 4, 13, and 18 months of age. We found that although ERα transcript levels declined from 
postnatal day 5 through 18 months of age, ERα protein levels remained stable. Importantly, E2- 
and ERα-regulated expression of the progesterone receptor gene demonstrated that, not only is 
ERα present, but it is functional in younger and in older females suggesting that age-related 
changes in estrogen responsiveness in the cerebral cortex are not due to the absence of ERα 
protein. 
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1. Introduction 
 17β-estradiol (E2) is a steroid hormone that regulates gene expression in the reproductive 
tract as well as non-reproductive tissues including the cardiovascular, skeletal, and nervous 
systems [1-3]. These tissues respond to E2 in part because they express the estrogen receptor 
(ER). ERα and ERβ are members of the steroid hormone receptor superfamily and are 
responsible for mediating the classical, genomic responses to E2 in target tissues [4].  
In the brain, E2 regulates sexual development and differentiation, synaptogenesis, 
learning and memory, mood, auditory perception, and neuroprotection [5-9]. The regions of the 
brain that have been reported to respond to E2 include the hypothalamus, hippocampus, 
amygdala, central auditory system, and cerebral cortex [3,5,10]. 
 ERα has several vital functions in the cerebral cortex. For example, it is important for 
neurogenesis [11] and protecting the cerebral cortex from ischemia-induced injury [8,12]. ERα 
also plays an important role in executive functioning of the prefrontal cortex which includes 
working memory, attention, and behavioral inhibition [13].  
Previous studies have examined ERα expression in the cerebral cortex [14-21]. ERα 
mRNA is highly expressed in the cerebral cortex shortly after birth but then decreases sharply 
beginning at postnatal day 10 (P10) [14-16]. ERα mRNA has also been detected in the cerebral 
cortices of aged female mice [17]. However, it has become clear that mRNA levels may not 
accurately reflect protein levels [22,23]. Thus, studies that use mRNA data to predict relative 
protein levels must be interpreted with caution.  
The studies that have examined the expression of ERα protein in the cerebral cortex have 
done so at one or two time points [15,18-21]. For example, Merchenthaler and coworkers used 
autoradiographic and immunohistochemical analyses to examine the distribution of ER protein in 
the adult female mouse brain [20]. This study demonstrated that the receptor was present at low 
levels in the cerebral cortex in 60-90 day old mice. While this study examined the spatial 
distribution of ERα in the cerebral cortex in great detail, it included only a single time point.  
Any alterations that occurred over time would not have been observed.  
In the current studies, the temporal pattern of ERα mRNA and protein expression in the 
cerebral cortex was followed over 18 months in hormonally intact female mice. Our work 
demonstrates that cortical ERα protein expression remains stable in these mice and that the ERα 
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protein present is functional suggesting that age-related changes in estrogen responsiveness in the 
cerebral cortex are not due to the absence of ERα protein. 
2. Materials and methods 
2.1. Mice  
 C57BL/6 breeding pairs for the generation of mouse pups (P5 and P17) and adult females 
(4 months) were obtained from Jackson Laboratory (Bar Harbor, ME). Retired female breeders 
were housed until 13 months for use as middle age animals. 18 month old C57BL/6 females 
were purchased from the National Institute on Aging. All mice were maintained on a 12 h 
light/dark schedule with access to water and food ad libitum. All procedures were performed in 
accordance with guidelines of the University of Illinois at Urbana-Champaign Institutional 
Animal Care and Use Committee and Division of Animal Resources.  
2.2. Estrous cycle staging 
4 month, 13 month, and 18 month old female mice were monitored for estrous cyclicity 
using vaginal cytology. Briefly, 5 µL of PBS was inserted into the vagina of each mouse and 
then removed, spread on a glass slide, allowed to air dry, fixed, and then nuclei were stained 
(3300-APD, Richard Allan Scientific, Pittsburgh, PA). Slides were imaged at 400x magnification 
using bright field illumination and the Leica DM 4000 B microscope. The stage of the estrous 
cycle was based on the presence or absence of leukocytes, cornified epithelial, and nucleated 
epithelial cells [24,25]. 4 month old mice exhibited at least two regular estrous cycles, the 13 
month old mice had irregular estrous cycles, and the 18 month old mice were in persistent 
diestrus. 4 month, 13 month, and 18 month old female mice were sacrificed while in diestrus. 
2.3. RT-PCR 
 Mice were anesthetized by inhalation of isoflurane and decapitated. Total RNA was 
isolated from cortices using RNAqueous reagents (Ambion, Life Technologies, Austin, TX) 
according to the manufacturer’s instructions. RNA concentrations were measured and cDNA was 
synthesized using the iScript kit (Bio-Rad, Hercules, CA) as described by the manufacturer. 2 µl 
of cDNA was combined with iQ SYBR Green Supermix (Bio-Rad, Hercules, CA), forward (5’-
AGTGTCTGTGATCTTGTCCAG-3’) and reverse (5’-TGTGTGCCTCAAATCCATCA-3’) 
primers for ERα that spanned exons 7 and 8, forward (5’-GGTGAGGCCGGTGCTGAGTATG-
3’) and reverse (5’-GACCCGTTTGGCTCCACCCTTC-3’) primers for GAPDH, or forward (5’-
CCGCCATACCTTAACTACCTGAG-3’) and reverse (5’-TGCTGCCCTTCCATTGCC-3’) 
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primers for PR and real-time PCR was carried out using a Bio-Rad iQ5 multicolor Real-Time 
PCR Detection System. Standard curves were created using cDNA equivalents of 0.25, 2.5 and 
25 ng of RNA and were run in triplicate with each primer set for each experiment.  
2.4. Immunofluorescence imaging 
Wild type P5, P17, 4 month, 13 month, and 18 month-old female mice were anesthetized 
by inhalation of isoflurane and decapitated. Whole brains were quickly harvested, bisected 
sagittally, and fixed in 4% paraformaldehyde for 18-24 h. Tissue was then transferred to a Leica 
ASP300 tissue processor for dehydration, clearing, and paraffin infiltration. Tissue was 
embedded in paraffin and four-micrometer coronal sections were mounted on charged glass 
slides. Tissue sections were deparaffinized in xylene, rehydrated in two changes of 100% then 
two changes of 95% ethanol, and washed with PBS. Sections were then heated in 10 mM citric 
acid, pH 6.0, for 20 min for antigen retrieval and remained in the citric acid until the temperature 
reached ~30°C (~2 h). The sections were then washed 3x with PBS, incubated in blocking buffer 
(PBS with 0.05% Tween-20 and 5% normal donkey serum) for 10 min, and incubated in 
blocking buffer with an ERα- specific antibody (1:600, ab31312, Abcam Inc., or 1:50, sc542, 
Santa Cruz Biotechnologies, Santa Cruz, CA) overnight at 4°C. The next day sections were 
washed 3x with PBS containing 0.1% Tween-20 (PBS-T). Then sections were incubated with 
DyLight 649-conjugated anti-rabbit IgG (1:500, Jackson ImmunoResearch Laboratories Inc., 
West Grove, PA) for 30 min in the dark at room temperature, washed 3x with PBS-T, incubated 
with 4′,6-diamidino-2-phenylindole (1:1000, DAPI) nucleic acid stain for 10 min at room 
temperature, washed 3x with PBS, and mounted with Pro-Long Gold antifade reagent (Life 
Technologies, Grand Island, NY). DAPI co-staining was included for each treatment to identify 
nuclei and ensure that similar numbers of cells were present. Control slides, which had not been 
exposed to primary antibody, and tissue sections from ERα knockout mice were processed and 
run in parallel. As an additional negative control, the ERα- specific antibody ab31312 was 
incubated with ten molar fold excess of purified, full-length human ERα protein prior to 
incubation of the antibody on brain tissue.  
2.5. Immunofluorescent image collection and quantitation 
All images were obtained with a 40x oil-immersion objective using a Leica DM 4000 B 
confocal microscope and imaging was performed using the Leica TCS SPE system and 
Application Suite Advanced Fluorescence software (Leica Microsystems, Inc., Bannockburn, 
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IL). Detector gain and offset, laser power, and bandwidth of emission collection were kept 
constant for all treatments in each experiment and adjusted so that images had a full range of 
pixel intensities (0–255) and saturation was minimized.  
Quantitative immunofluorescent analysis of ERα staining in brain tissue was performed 
by using DAPI staining to count the total number of cells in 3-6 fields from 3-4 mice. The 
percent of cells expressing ERα was determined. 
2.6. Immunohistochemistry 
Immunohistochemistry was performed as described for immunofluorescence except that 
after antigen retrieval endogenous peroxidases were blocked with 3% hydrogen peroxide for 20 
min at room temperature. After three 5 min washes in PBS, sections were incubated in blocking 
buffer for 10 min and then incubated in blocking buffer with a PR-specific antibody (1:50, 
A0098, Dako, Carpinteria, CA) overnight at 4°C. Sections were washed with PBS-T 3x for 5 
min each and then incubated with biotin-conjugated secondary antibody (1:200, Jackson 
ImmunoResearch Laboratories, Inc.) for 30 min at room temperature, followed by three 5 min 
washes with PBS-T. The ABC Peroxidase Staining kit (1:100 dilution of each Reagent A and B 
in PBS, 32020, Thermo Scientific, Rockford, IL) was applied to the sections for 30 min. After 
three washes with PBS, staining was visualized with peroxidase-sensitive Sigmafast 3,3’-
Diaminobenzidine tablets (DAB, Sigma, St. Louis, MO) for 10 min. Sections were 
counterstained with 0.1% methyl green (Sigma, St. Louis, MO) for 5 min at 60°C, dehydrated in 
ethanol, cleared in xylene, and mounted with Permount (Fisher Scientific, Pittsburgh, PA). 
Control slices, which had not been exposed to primary antibody, were processed in parallel. 
Images were obtained at 40x using a Leica DM 4000 B confocal microscope with the Retiga 
2000R digital camera and Image Pro Plus image collection and analysis software. 
2.7. Statistics 
Combined data are expressed as the mean ± SEM. SAS version 9.3 (SAS Institute Inc., Cary, 
NC) was used for statistical analysis. ERα and PR transcript levels and the percent of ERα-positive cells 
were compared using one-way analysis of variance (ANOVA) and Tukey’s post-hoc test. A p value of 
<0.05 was considered statistically significant (95% confidence interval).  
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3. Results 
3.1. ERα transcript levels in the cerebral cortex throughout the female lifespan 
 Much of the previous work examining ERα expression in the cerebral cortex has 
analyzed ERα transcript levels in rodents either shortly after birth or in adults [14-17]. Therefore, 
to examine ERα expression across a broad range of ages in a single study, we measured ERα 
mRNA at five time points in hormonally intact females. We noted a significant decline in ERα 
transcript levels after P5 (Fig. 4.1), which is in agreement with previous work [15]. Another 
significant decrease occurred at 13 months and was sustained through 18 months. These results 
demonstrated that ERα mRNA levels decline with age in intact female mice, most notably after 
P5, and is consistent with data from previous studies [14-16,26]. However, in contrast with 
previous studies in which ERα mRNA levels were very low at P25 [15,16,26] and another study 
in which ERα mRNA was not detected in young (3-4 month) female mice [14], our work 
demonstrates that ERα mRNA transcripts were detected at each of the ages examined. 
3.2. ERα protein expression in the cerebral cortex throughout the female lifespan 
 While mRNA levels provide valuable information, protein, not mRNA, is the active end 
product of gene expression. Therefore, ERα protein expression was examined in the cerebral 
cortex of female mice using immunofluorescence at various ages. ERα protein was clearly seen 
in the cerebral cortex of female mice at P5 (Fig. 4.2A). While the DAPI staining suggests that the 
number and density of cells in the cortex had decreased by P17 (Fig. 4.2B), this synaptic pruning 
and subsequent cell death is a normal occurrence during the first two weeks of postnatal brain 
development [27-30], ERα protein expression continued to be detected at high levels in the 
cerebral cortex. 4 month old female mice (Fig. 4.2C) expressed similar levels of ERα protein. 
Even in middle age (13 months, Fig. 4.2D) and aged (18 month, Fig. 4.2E) mice, ERα protein 
expression was clearly present in the cerebral cortex.  
Image analysis of cerebral cortices from female mice at P5, P17, 4 months, 13 months, or 
18 months indicated that 81%, 77%, 72%, 67%, or 70% of the total DAPI-stained cells expressed 
ERα, respectively (Fig. 4.2F). While a slight decrease in the total percent of cells expressing 
ERα was observed over time, this decline was not statistically significant. These results 
demonstrate that ERα protein expression remained high in the cerebral cortex of hormonally 
intact females, even in middle age and aged mice.  
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3.3. Anti-ERα antibody recognized ERα protein in the cerebral cortex 
 Since ERα protein levels were very different from the ERα transcript levels, we wanted 
to verify the specificity of our ERα primary antibody. Figure 4.3A demonstrates the typical 
staining pattern and intensity for ERα that was observed when the cerebral cortex was incubated 
with primary and secondary antibodies. However, when the anti-ERα primary antibody 
(ab31312) was incubated with purified, full-length human ERα protein and then added to brain 
slices from the same mouse, no staining was observed (Fig. 4.3B). When the primary antibody 
was omitted and only the secondary antibody was used, no staining was observed (Fig. 4.3C).  
 As final evidence that the anti-ERα primary antibody was specific, brain slices from ERα 
knockout or wild type mice were stained. As shown in figure 4.3D, staining was only observed 
in wild-type mice. Thus, our antibody was specific for ERα and did not recognize other epitopes. 
3.4. Expression of an ERα-regulated gene in the cerebral cortex 
 Our studies thus far have demonstrated that ERα mRNA and protein were present in the 
cerebral cortex of mice from P5 through 18 months of age. To investigate whether ERα was 
functional at each of the ages examined, we evaluated mRNA and protein expression levels of 
the E2-responsive gene progesterone receptor (PR) in the cerebral cortex of hormonally intact 
female mice at various ages. PR mRNA expression declined slightly, but not significantly, from 
P5 to P17 but increased significantly in mice 4 months of age (Fig. 4.4A). In 13 and 18 month 
old mice, PR mRNA expression significantly declined to levels below P5. To examine PR 
protein levels in female mice at each age, immunohistochemistry was performed using a PR-
specific antibody. Our work demonstrated that PR protein is present at P5, P17, 4 months, 13 
months, and 18 months of age (Fig. 4.4B-F). Thus, while ERα protein levels remained stable 
throughout the lifespan of intact female mice, ERα-regulated PR mRNA diminished in the 13 
and 18 month old mice and PR protein was present at each age. These results indicate that the 
ERα protein present in the cerebral cortex at each age was functional and influenced 
transcription of PR.  
4. Discussion  
Because ERα mediates many of the cellular responses of the cerebral cortex to E2 such as 
cognition [13] and neuroprotection [8,11,12], this protein plays a critical role in neurological 
function.  While a number of studies have examined ERα mRNA levels in the cerebral cortex, 
   
    
65 
there has been some question about whether ERα protein is present [15,18,21]. We have now 
demonstrated that ERα protein was present in the cerebral cortex of newborn, middle aged, and 
older female mice. 
Although the expression of ERα has been examined in the hypothalamus and 
hippocampus in detail, far less is known about the expression of ERα in the cerebral cortex. Our 
studies focused on the cerebral cortex since this region of the brain is more susceptible to 
ischemic damage than other brain regions [6,7,31-35] and we were interested in determining 
whether ERα might be present in the cerebral cortex of older animals and capable of mediating 
estrogen responsiveness.  
Previous studies with ERα null mice have demonstrated that PR gene expression depends 
on ERα expression [36-38]. We have now shown that PR expression is sustained in the cerebral 
cortex over 18 months suggesting that not only was ERα present, but that it was functional and 
was capable of enhancing PR mRNA and protein levels.  Although the level of PR mRNA varied 
somewhat with age with the most abundant transcripts being present during peak reproductive 
age, immunohistochemistry suggested that E2- and ERα-mediated expression of PR protein was 
sustained in younger and in older female animals.  
Expression of ERα has been examined in the rodent brain using ligand binding, 
autoradiography, immunohistochemistry, in-situ hybridization, and PCR analyses [14-
16,19,20,39,40]. While newer techniques have made it possible to distinguish between ERα and 
ERβ, it is clear that ERα is responsible for E2-mediated neuroprotection [8,9]. Thus, our studies 
focused on ERα protein expression. In fact, ERα protein expression is sustained in the cerebral 
cortex suggesting that E2 may mediate its neuroprotective effect in younger as well as older 
females. 
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Figures and Figure Legends 
 
Fig. 4.1 ERα transcript levels decline in the cerebral cortex throughout the female lifespan. Total 
RNA was isolated from the cortex of female mice at postnatal day 5 (P5), postnatal day 17 (P17), 
4 months (4 mo), 13 months (13 mo), and 18 months (18 mo) of age. cDNA was synthesized and 
ERα mRNA levels were determined using quantitative real time PCR. The relative fold change 
was calculated using the delta-delta Ct method and each sample was normalized to the amount of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA present. The mean relative fold 
change at each age is shown ± SEM. One-way analysis of variance (ANOVA) and Tukey’s post-
hoc test was used to detect whether there were significant differences in ERα mRNA from 
female mice at P5 compared with mice at P17, 4 mo, 13 mo, and 18 mo (* p < 0.05) of age.  
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Fig. 4.2 ERα protein expression remains stable in the cerebral cortex throughout the female lifespan. 
Brain sections from female mice at (A) postnatal day 5, (B) postnatal day 17, (C) 4 months, (D) 13 
months, or (E) 18 months of age were stained using immunofluorescence with an ERα-specific antibody 
and the cerebral cortex was examined. DAPI staining was included to identify cortical cell nuclei. Scale 
bars indicate 25 µm. (F) Quantitation of ERα protein expression was performed by determining the 
percent of ERα-positive cells ± SEM. 
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Fig. 4.3 Anti-ERα antibody recognizes ERα in the cerebral cortex. Brain sections were obtained from 
13 month old female mice and using the ERα-specific antibody ab31312 (A) was not or (B) was pre-
incubated with full-length human ERα protein. (C) The ERα primary antibody was omitted so that only 
secondary antibody was used. (D) Brain sections from wild type (WT) or ERα knockout (KO) adult 
female mice were stained using the ERα-specific antibody sc542. Scale bars indicate 25 µm. 
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Fig. 4.4 PR transcript levels decline but PR protein is present in the cerebral cortex throughout 
the female lifespan. (A) Total RNA was isolated from the cortex of female mice at P5, P17, 4 mo, 
13 mo, and 18 mo. cDNA was synthesized and PR mRNA levels were determined using 
quantitative real time PCR. The relative fold change was calculated using the delta-delta Ct 
method and each sample was normalized to the amount glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA present. The mean relative fold change at each age is shown ± 
SEM. One-way analysis of variance (ANOVA) and Tukey’s post-hoc test was used to detect 
significant differences in ERα mRNA from female mice at P5 compared with mice at P17, 4 mo, 
13 mo, and 18 mo (* p < 0.05) of age. Brain sections from (B) P5, (C) P17, (D) 4 mo, (E) 13 mo, 
and (F) 18 mo old female mice were stained using immunohistochemistry with a PR-specific 
antibody to examine the cerebral cortex. Scale bars indicate 25 µm. 
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CHAPTER FIVE 
Conclusions 
 
Summary 
 The work in this dissertation reveals several novel findings. First, I used a rodent model 
of amyotrophic lateral sclerosis (ALS) in which Cu/Zn superoxide dismutase was mutated to 
examine nitrotyrosine levels in spinal cord sections and demonstrated that oxidative protein 
damage is an early feature of ALS that appears prior to motor symptoms. This work extends our 
understanding of the development and progression of protein damage in ALS and, subsequently, 
progression of motor symptoms. Second, I showed that ovariectomized female mice that had 
been treated with E2 and exposed to hypoxia had increased protein expression of apurinic 
endonuclease in the cerebral cortex. We believe that this E2-mediated increase in apurinic 
endonuclease expression contributes to a decline of oxidative DNA damage in the cerebral 
cortex of mice that had been pretreated with E2 and then exposed to hypoxia. Finally, using 
hormonally intact female mice, I demonstrated that ERα protein expression in the cerebral cortex 
remains stable and functional up to 18 months of age. Taken together, these studies provide data 
that may be valuable for improving the diagnosis and outcome of oxidative stress-induced 
diseases. 
Ligand specificity 
Human studies have demonstrated that the decline in ovarian hormones following 
menopause contributes to an increased risk of ischemic stroke and neurodegenerative disorders 
in women [1,2]. One means by which a woman may overcome these debilitating symptoms 
associated with menopause is the administration of estrogen [3-6]. Because systemic exposure to 
E2 may have unintentional side effects, the use of a brain-specific estrogen could be extremely 
beneficial [7]. A well-known example of one selective estrogen receptor modulator influencing 
ER activity in one tissue but not in another is tamoxifen. In fact, tamoxifen has been used for 
decades in the clinic as an antagonist of ERα to treat breast cancer while maintaining bone 
mineral density and improving cholesterol levels [8-11]. In the brain, selective estrogen receptor 
modulators have been shown to reduce infarct size, inflammation, superoxide production, 
oxidative DNA damage, and lipid peroxidation following ischemia but do not act as estrogen 
receptor agonists in breast and uterine tissue [7,12-15].  
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In addition to tissue specificity, ligands also exhibit receptor specificity. While E2 binds 
to both ERα and ERβ, and ERβ has been implicated in E2-mediated neuroprotection [16-18], 
ERα is the primary receptor responsible for mediating E2-induced neuroprotection. This was 
demonstrated by a reduced infarct volume in ERβ-, but not in ERα-knockout mice that had been 
ovariectomized, exposed to E2, and then subjected to middle cerebral artery occlusion [19-21]. 
Additionally, the ERα-selective agonist propyl pyrazole triol (PPT) is neuroprotective in a rodent 
model of Parkinson’s disease and deletion of ERα increases the risk of developing Parkinsonian 
symptoms [22-24]. However, pretreatment with the ERβ-selective agonist diarylpropiolnitril 
(DPN) did not decrease infarct size or improve sensorimotor function in rats following middle 
cerebral artery occlusion [25]. These studies demonstrate the importance of ERα in protecting 
the brain from ischemic damage and other neurodegenerative insults and highlight its role as the 
primary ER mediating these effects in the brain. 
Global analysis 
While the work in this dissertation provides valuable information and details about 
mechanisms involved in E2-mediated neuroprotection, a more global and unbiased approach to 
elucidate mechanisms regulating E2-mediated neuroprotection is RNA sequencing technology 
[26]. In fact, studies in our laboratory using RNA sequencing are underway to uncover pathways 
and additional genes that are altered in the cerebral cortex by E2 and hypoxia. Initial findings 
suggest that E2 regulates many genes in the cerebral cortex that had previously not been 
identified as E2-responsive in the brain. Biological processes and pathways associated with E2-
regulated genes include chromosome organization, gap junction and cell adhesion molecules, 
inflammation, and MAPK signaling.  
Conclusions 
The metabolic needs of the brain are the greatest of any organ in the body and this results 
in the greatest production of ROS. By understanding the protein and DNA damage that results 
from ROS exposure, our work provides important data that can be used to decrease this ROS-
induced damage in the brain. Clinical applications that utilize this information may result in 
treatments that slow the progression and improve the outcome of diseases such as ALS and 
ischemia. The need for improved, tissue-specific therapies that can protect women from ischemic 
stroke and other neurodegenerative disorders without detrimental side effects is even more 
pressing than ever.  
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